Company: BIAF
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001641172-25-025247
Chunk: 46

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-22
Form: DRS
Chunk 46
---
 intellectual property and      
 title matters and compliance with various laws such as the Foreign Corrupt Practices Act; and                                            |
| ● | covenants                                                                                                                                
 regarding matters such as registration of shares issued and issuable upon exercise of the Common Stock Purchase Warrants, no integration 
 with other offerings, no shareholder rights plans, use of proceeds, indemnification of purchasers, reservation and listing of Common     
 Stock, and no subsequent equity sales for [●] days.                                                                                      |

Delivery of the shares of Common Stock, Pre-Funded Warrants and August 2025 Warrants offered hereby is expected to occur on or about *, 2025, subject to satisfaction of certain customary closing conditions.

Fees and Expenses

The following table shows the per share price and total cash fees we will pay to the Placement Agent in connection with the sale of the securities pursuant to this prospectus.

|                                |     | Per Share and Common Stock Purchase Warrant |     | Per Pre-Funded Warrant and Common Stock Purchase Warrant |     | Total |
|:-------------------------------|:----|:--------------------------------------------|:----|:---------------------------------------------------------|:----|:------|
| Public offering price          |     | $                                           |     | $                                                        |     | $     |
| Placement Agent fees           |     | $                                           |     | $                                                        |     | $     |
| Proceeds before expenses to us |     | $                                           |     | $                                                        |     | $     |

We have agreed to pay the Placement Agent an aggregate fee equal to [●]% of the aggregate gross proceeds received in the offering. We have also agreed to pay the Placement Agent a management fee equal to [●]% of the gross proceeds raised in this offering and to reimburse the Placement Agent for its legal fees and expenses and other out-of-pocket expenses in an amount up to $[●], non-accountable expenses of $[●] and clearing expenses of $[●].

| 28 |

We estimate the total expenses of this offering paid or payable by us, exclusive of the Placement Agent’s cash fee and expenses payable by us, will be approximately $[●]. After deducting the fees and expenses due to the Placement Agent and our estimated expenses in connection with this offering, assuming we sell all of the shares and accompanying warrants offered hereby, we expect the net proceeds from this offering will be approximately $[●] million (assuming $[●] million on gross proceeds are received).

Placement Agent Warrants

In addition, we have agreed to issue to the